½ÃÀ庸°í¼­
»óǰÄÚµå
1602189

°æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : À¯Çü, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Transdermal Drug Delivery System Market by Type (Transdermal Patches, Transdermal Semisolids), Application (Cardiovascular Diseases, Central Nervous System Disorders, Hormonal Applications), End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 193 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

°æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº 2023³â¿¡ 69¾ï 8,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â¿¡´Â 73¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 5.06%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 98¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

°æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ(TDDS)Àº °æ±¸ ¶Ç´Â Áֻ縦 ´ëüÇÒ ¼ö ÀÖ´Â ºñħ½ÀÀû ¹æ¹ýÀ¸·Î ÇǺθ¦ ÅëÇØ ¾à¹°À» Åõ¿©ÇÏ´Â ½Ã½ºÅÛÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Çʿ伺Àº ÀϰüµÈ Ä¡·á È¿°ú, ȯÀÚ ¼øÀÀµµ Çâ»ó, ±âÁ¸ Àü´Þ ¸ÞÄ¿´ÏÁò¿¡¼­ ÈçÈ÷ ¹ß»ýÇÏ´Â ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇÑ ¿ä±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó »ý°Ü³µ½À´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº ÅëÁõ °ü¸®, È£¸£¸ó Ä¡·á, ´ÏÄÚÆ¾ ±Ý¿¬ µî ´Ù¾çÇÑ Ä¡·á ºÐ¾ß¿¡ Àû¿ë °¡´ÉÇϸç, ÇǺΰú¿¡¼­ ¼øÈ¯±â Áúȯ¿¡ À̸£±â±îÁö ´Ù¾çÇÑ ÃÖÁ¾ ¿ëµµ¿¡ ¹ü¿ëÀûÀ¸·Î Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀº ¾à¹° Á¦Á¦ ±â¼úÀÇ ¹ßÀü, ¸¸¼ºÁúȯ Áõ°¡, ¹«Åë ¾à¹° Åõ¿©¿¡ ´ëÇÑ È¯ÀÚ ¼±È£µµ, Çõ½ÅÀûÀÎ ¾à¹°Àü´Þ ½Ã½ºÅÛÀ¸·ÎÀÇ Àüȯ¿¡ µû¶ó Å©°Ô Á¿ìµÉ °ÍÀÔ´Ï´Ù. ³ª³ëÅ×Å©³î·¯Áö°ú »ýü Àç·á¸¦ Ȱ¿ëÇÏ¿© ÆéƼµå³ª ¹é½Å°ú °°Àº º¹ÀâÇÑ Ä¡·áÁ¦¸¦ Àü´ÞÇÒ ¼ö ÀÖ´Â ´Ù±â´É TDDS ±â¼úÀ» °³¹ßÇÒ ¼ö ÀÖ´Â ±âȸ´Â dzºÎÇÕ´Ï´Ù. ±â¾÷Àº ¿¬±¸ Çù·Â¿¡ ÅõÀÚÇϰí Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ÀáÀç·ÂÀ» Ȱ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÃÀåÀº ³ôÀº °³¹ß ºñ¿ë, ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç, ÇǺΠÀڱؼº ¹®Á¦ µîÀÇ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖÀ¸¸ç, ÀÌ´Â º¸±Þ¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. È¿°úÀûÀΠħÅõ ÃËÁøÁ¦ ¹èÇÕÀº ¿©ÀüÈ÷ Áß¿äÇÑ ¿¬±¸ ºÐ¾ß·Î, ºÎÀÛ¿ë ¾øÀÌ ¾à¹° ħÅõ¸¦ ÃÖÀûÈ­ÇÒ ¼ö ÀÖ´Â Çõ½ÅÀûÀÎ ¹°Áú°ú ±â¼ú¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ¼Òºñ µ¿ÇâÀÌ ¸ÂÃãÇü ÀÇ·á·Î À̵¿ÇÔ¿¡ µû¶ó Çõ½ÅÀÇ ÇÙ½É ¿µ¿ªÀº µ¥ÀÌÅÍ ºÐ¼® ¹× ¿¹Ãø ¸ðµ¨¸µ¿¡ AI¸¦ Ȱ¿ëÇÏ¿© ȯÀÚ °³°³ÀÎÀÇ Çʿ信 µû¶ó ¸ÂÃãÇü °æÇÇ ¼Ö·ç¼ÇÀ» ¸¸µå´Â °ÍÀÔ´Ï´Ù. ½ÃÀåÀº ¿ªµ¿ÀûÀ̸ç, Á¦¾à ´ë±â¾÷°ú ½Å»ý ½ºÅ¸Æ®¾÷ÀÌ ±ÕÇüÀ» ÀÌ·ç¸ç Çõ½ÅÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Àå±âÀûÀÎ ¼ºÀåÀ» ¿øÇÏ´Â ±â¾÷Àº ¾÷°è °£ ÆÄÆ®³Ê½Ê°ú TDDSÀÇ À¯È¿¼º ¹× ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» Áö¼ÓÀûÀ¸·Î °³¼±ÇÏ´Â °ÍÀ» ¿ì¼±¼øÀ§¿¡ µÎ¾î ÀÚ»ç Á¦Ç°ÀÌ ±â¼ú ¹× ȯÀÚ Ä¡·á µ¿ÇâÀÇ ÃÖÀü¼±¿¡ ¼­µµ·Ï ÇØ¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ[2023] 69¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø³â[2024] 73¾ï 2,000¸¸ ´Þ·¯
¿¹Ãø³â[2030] 98¾ï 7,000¸¸ ´Þ·¯
CAGR(%) 5.06%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

°æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¿ªÀû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¸¸¼ºÁúȯÀÇ À¯Çà°ú È¿°úÀûÀÎ ¾à¹°Àü´ÞÀÇ Çʿ伺
    • 3¼¼´ëÀÇ ±Þ¼ÓÇÑ º¸±Þ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÆÐÄ¡ »ç¿ë½Ã ÇǺΠÀÚ±Ø ¹× ÇǺΠ°ú¹Î¹ÝÀÀ¿¡ ´ëÇÑ ¿ì·Á
  • ½ÃÀå ±âȸ
    • °æÇÇÀû ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ Áö¼ÓÀûÀÎ ¿¬±¸°³¹ß
    • Á¦¾à»ç ¹× TDDS °ø±Þ¾÷üÀÇ ¹«±âÀû ¼ºÀå Àü·«
  • ½ÃÀå °úÁ¦
    • °æÇÇ Èí¼öÇü Å×ÀÌÇÁ Á¦Á¦ÀÇ ¾à¹° Àå¾Ö À§Çè°ú Á¦Ç° ȸ¼ö °¡´É¼º

Porter's Five Forces: °æÇǾ๰Àü´Þ½Ã½ºÅÛ ½ÃÀå °ø·«À» À§ÇÑ Àü·«Àû Åø

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : °æÇǾ๰Àü´Þ½Ã½ºÅÛ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ·Â ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® °æÇǾ๰Àü´Þ½Ã½ºÅÛ ½ÃÀå¿¡¼­ÀÇ °æÀï»óȲ ÆÄ¾Ç

°æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀº º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇÏ¿© »ç¿ëÀÚ°¡ Àü·«Àû ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù. :

1. ½ÃÀå ħÅõµµ : ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æ¿¡ ´ëÇÑ »ó¼¼ÇÑ °ËÅä.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù. :

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÔ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : À¯Çüº°

  • °æÇÇÆÐÄ¡
    • ¾àÁ¦ Á¢Âø ÆÐÄ¡
    • ¸ÅÆ®¸¯½º ÆÐÄ¡
    • ¸¶ÀÌÅ©·Î´Ïµé ÆÐÄ¡
    • ¸®Àú¹ö¸· ÆÐÄ¡
  • °æÇÇ Èí¼öÇü ¹Ý°íÇüÁ¦
    • Á©
    • ¿¬°í
    • ½ºÇÁ·¹ÀÌ

Á¦7Àå °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ¿ëµµº°

  • ½ÉÇ÷°üÁúȯ
  • ÁßÃ߽Űæ°è Áúȯ
  • È£¸£¸ó ÀÀ¿ë
  • ÅëÁõ °ü¸®
  • °æÇÇ¿¡½ºÆ®·Î°Õ ¿ä¹ý

Á¦8Àå °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ȨÄÉ¾î ¼³Á¤
  • º´¿ø¡¤Å¬¸®´Ð

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®

±â¾÷ ¸®½ºÆ®

  • Novartis International AG
  • Viatris Inc.
  • 3M Company
  • Biotts Inc.
  • Nitto Denko Corporation
  • Medherant Limited
  • Lead Chemical Co., Ltd.
  • Zynerba Pharmaceuticals, Inc.
  • Purdue Pharma L.P.
  • UCB S.A.
  • Johnson & Johnson Services, Inc.
  • Sorrento Therapeutics, Inc.
  • Sparsha Pharma International Pvt. Ltd.
  • IntelGenx Corp.
  • Transdermal Therapeutics, Inc.
  • Toa Eiyo Ltd.
  • Gensco Pharma
  • Bayer AG
  • Luye Life Sciences Group
  • Nutriband Inc.
  • Zhongshan Senwell Bio Technology Co., Ltd.
  • Starton Therapeutics
  • Lavipharm S.A.
  • Kindeva Drug Delivery L.P.
  • Hisamitsu Pharmaceutical Co., Inc.
  • IBSA Farmaceutici Italia Srl
  • AdhexPharma, SAS
  • Toyo Ink SC Holdings Co., Ltd.
  • DuPont de Nemours, Inc.
  • Boehringer Ingelheim International GmbH
KSA 24.12.10

The Transdermal Drug Delivery System Market was valued at USD 6.98 billion in 2023, expected to reach USD 7.32 billion in 2024, and is projected to grow at a CAGR of 5.06%, to USD 9.87 billion by 2030.

The transdermal drug delivery system (TDDS) involves administering medication through the skin, offering a non-invasive alternative to oral or injectable methods. Its necessity arises from the growing demand for consistent therapeutic effects, improved patient compliance, and minimized side effects typically associated with traditional delivery mechanisms. This system is applicable across several therapeutic areas, including pain management, hormonal treatment, and nicotine cessation, making it versatile for a broad end-use scope, ranging from dermatology to cardiovascular health. Market growth is significantly influenced by advancements in drug formulation technologies, increased prevalence of chronic diseases, patient preference for painless drug administration, and a shifting focus towards innovative drug delivery systems. Opportunities abound in the development of multifunctional TDDS technology capable of delivering complex therapeutics, such as peptides and vaccines, by leveraging nanotechnology and biomaterials. Companies can benefit from investing in research collaborations and expanding their product portfolios to tap into these potentials. However, the market faces challenges such as high development costs, stringent regulatory requirements, and skin-related irritation issues, which could hamper widespread adoption. The inclusion of effective penetration enhancers remains a critical research area, focusing on innovative substances and technologies that can optimize drug permeation without adverse effects. As consumption trends tilt towards personalized medicine, a significant area of innovation lies in creating more tailored transdermal solutions that align with individual patient needs, utilizing data analytics and AI in predictive modeling. The market is dynamic, with a balanced representation of pharmaceutical giants and emerging startups leading innovation. Firms aiming for long-term growth should prioritize cross-industry partnerships and continual improvements in TDDS efficacy and safety profiles, ensuring that their offerings remain at the forefront of technology and patient care trends.

KEY MARKET STATISTICS
Base Year [2023] USD 6.98 billion
Estimated Year [2024] USD 7.32 billion
Forecast Year [2030] USD 9.87 billion
CAGR (%) 5.06%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Transdermal Drug Delivery System Market

The Transdermal Drug Delivery System Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of chronic diseases and the need for effective drug delivery
    • Surging adoption of third-generation transdermal drug delivery system
  • Market Restraints
    • Concerns associated with irritation or skin sensitivity over patch usage
  • Market Opportunities
    • Ongoing research & development in transdermal drug delivery system
    • Inorganic growth strategies between pharmaceutical companies and TDDS vendors
  • Market Challenges
    • Probable risk of drug failure through transdermal systems and product recalls

Porter's Five Forces: A Strategic Tool for Navigating the Transdermal Drug Delivery System Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Transdermal Drug Delivery System Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Transdermal Drug Delivery System Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Transdermal Drug Delivery System Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Transdermal Drug Delivery System Market

A detailed market share analysis in the Transdermal Drug Delivery System Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Transdermal Drug Delivery System Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Transdermal Drug Delivery System Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Transdermal Drug Delivery System Market, highlighting leading vendors and their innovative profiles. These include Novartis International AG, Viatris Inc., 3M Company, Biotts Inc., Nitto Denko Corporation, Medherant Limited, Lead Chemical Co., Ltd., Zynerba Pharmaceuticals, Inc., Purdue Pharma L.P., UCB S.A., Johnson & Johnson Services, Inc., Sorrento Therapeutics, Inc., Sparsha Pharma International Pvt. Ltd., IntelGenx Corp., Transdermal Therapeutics, Inc., Toa Eiyo Ltd., Gensco Pharma, Bayer AG, Luye Life Sciences Group, Nutriband Inc., Zhongshan Senwell Bio Technology Co., Ltd., Starton Therapeutics, Lavipharm S.A., Kindeva Drug Delivery L.P., Hisamitsu Pharmaceutical Co., Inc., IBSA Farmaceutici Italia Srl, AdhexPharma, SAS, Toyo Ink SC Holdings Co., Ltd., DuPont de Nemours, Inc., and Boehringer Ingelheim International GmbH.

Market Segmentation & Coverage

This research report categorizes the Transdermal Drug Delivery System Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Transdermal Patches and Transdermal Semisolids. The Transdermal Patches is further studied across Drug-In-Adhesive Patches, Matrix Patches, Microneedle Patches, and Reservoir Membrane Patches. The Transdermal Semisolids is further studied across Gels, Ointments, and Sprays.
  • Based on Application, market is studied across Cardiovascular Diseases, Central Nervous System Disorders, Hormonal Applications, Pain Management, and Transdermal Estrogen Therapy.
  • Based on End User, market is studied across Home Care Settings and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and the need for effective drug delivery
      • 5.1.1.2. Surging adoption of third-generation transdermal drug delivery system
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with irritation or skin sensitivity over patch usage
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research & development in transdermal drug delivery system
      • 5.1.3.2. Inorganic growth strategies between pharmaceutical companies and TDDS vendors
    • 5.1.4. Challenges
      • 5.1.4.1. Probable risk of drug failure through transdermal systems and product recalls
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Ongoing regulatory and government approvals for transdermal patches
    • 5.2.2. Application: Need for minimally invasive drug delivery systems for management of cardiovascular diseases
    • 5.2.3. End-User: Preference for self-administration of drugs leading to demand for drug delivery systems that can be implemented in home care settings
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Transdermal Drug Delivery System Market, by Type

  • 6.1. Introduction
  • 6.2. Transdermal Patches
    • 6.2.1. Drug-In-Adhesive Patches
    • 6.2.2. Matrix Patches
    • 6.2.3. Microneedle Patches
    • 6.2.4. Reservoir Membrane Patches
  • 6.3. Transdermal Semisolids
    • 6.3.1. Gels
    • 6.3.2. Ointments
    • 6.3.3. Sprays

7. Transdermal Drug Delivery System Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiovascular Diseases
  • 7.3. Central Nervous System Disorders
  • 7.4. Hormonal Applications
  • 7.5. Pain Management
  • 7.6. Transdermal Estrogen Therapy

8. Transdermal Drug Delivery System Market, by End User

  • 8.1. Introduction
  • 8.2. Home Care Settings
  • 8.3. Hospitals & Clinics

9. Americas Transdermal Drug Delivery System Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Transdermal Drug Delivery System Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Transdermal Drug Delivery System Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Approved in China for the Treatment of Alzheimer's Disease
    • 12.3.2. Satio Wins USD 3.5 Million Contract To Develop At-Home Transdermal Drug Delivery Device
    • 12.3.3. LTS Completes Its Entry Into Large Molecule Drug Delivery With The Acquisition Of The Sorrel Wearable Injection Device Business
    • 12.3.4. DifGen Pharmaceuticals Acquires Aveva Drug Delivery Services Inc.
    • 12.3.5. Zydus Lifesciences gets Final Approval from the U.S. FDA to Market Estradiol Transdermal System
    • 12.3.6. Kindeva Merges with Meridian to Create Global CDMO Specializing in Drug-Device Combinations
    • 12.3.7. LTS Lohmann Leads Investment in Needle-Free Delivery Specialist
    • 12.3.8. Love Pharma Moves To Buy Transdermal Opioid-Use Disorder Player
    • 12.3.9. Corium Launches ADLARITY (donepezil transdermal system) for Patients with Alzheimer's Dementia
    • 12.3.10. Lowenstein Represents Pharma Tech LTS Lohmann Therapy Systems, Corp. in Acquisition of Tapemark Inc.

Companies Mentioned

  • 1. Novartis International AG
  • 2. Viatris Inc.
  • 3. 3M Company
  • 4. Biotts Inc.
  • 5. Nitto Denko Corporation
  • 6. Medherant Limited
  • 7. Lead Chemical Co., Ltd.
  • 8. Zynerba Pharmaceuticals, Inc.
  • 9. Purdue Pharma L.P.
  • 10. UCB S.A.
  • 11. Johnson & Johnson Services, Inc.
  • 12. Sorrento Therapeutics, Inc.
  • 13. Sparsha Pharma International Pvt. Ltd.
  • 14. IntelGenx Corp.
  • 15. Transdermal Therapeutics, Inc.
  • 16. Toa Eiyo Ltd.
  • 17. Gensco Pharma
  • 18. Bayer AG
  • 19. Luye Life Sciences Group
  • 20. Nutriband Inc.
  • 21. Zhongshan Senwell Bio Technology Co., Ltd.
  • 22. Starton Therapeutics
  • 23. Lavipharm S.A.
  • 24. Kindeva Drug Delivery L.P.
  • 25. Hisamitsu Pharmaceutical Co., Inc.
  • 26. IBSA Farmaceutici Italia Srl
  • 27. AdhexPharma, SAS
  • 28. Toyo Ink SC Holdings Co., Ltd.
  • 29. DuPont de Nemours, Inc.
  • 30. Boehringer Ingelheim International GmbH
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦